Abstract The noninvasive detection of the presence and functional significance of coronary artery stenosis is important in the diagnosis, risk assessment, and management of patients with known or suspected coronary artery disease. Quantitative assessment of myocardial perfusion can provide an objective and reproducible estimate of myocardial ischemia and risk prediction. Positron emission tomography, cardiac magnetic resonance, and cardiac computed tomography perfusion are modalities capable of measuring myocardial blood flow and coronary flow reserve. In this review, we will discuss the technical aspects of quantitative myocardial perfusion imaging with positron emission tomography, cardiac magnetic resonance imaging, and computed tomography, and its emerging clinical applications.
Introduction
Noninvasive delineation of the presence of coronary artery stenosis and its functional significance are important in the diagnosis, risk assessment, and management of patients with known or suspected coronary artery disease (CAD). Myocardial perfusion imaging is the most widely used technique in the evaluation of the functional significance of CAD. It can be assessed noninvasively by single-photon emission computed tomography (SPECT), stress echocardiography, positron emission tomography (PET), cardiac magnetic resonance imaging (CMR), and cardiac computed tomographic perfusion (CTP). Although qualitative or semiquantitative evaluation of regional perfusion is the most commonly used clinical approach, it has limitations in the assessment of the extent of CAD, especially in patients with multivessel disease [1] . Another limitation of semiquantitative perfusion assessment that is applicable to all imaging techniques is its inability to delineate the extent and severity of diffuse atherosclerosis and microvascular dysfunction. In addition, quantitative myocardial perfusion may eliminate interobserver bias from semiquantitative or qualitative interpretations. In this manuscript, we will review the technical aspects of quantitative myocardial perfusion imaging with positron emission tomography, cardiac magnetic resonance imaging and computed tomography, and discuss its emerging clinical applications.
Technical Considerations
In normal coronary vessels, changes in myocardial oxygen demand trigger a local endothelial-mediated release of nitric oxide that leads to arteriolar dilatation and decreased resistance in the microvasculature, which results in increased myocardial perfusion. In the setting of atherosclerosis, however, the presence of upstream coronary stenosis, diffuse atherosclerosis, and microvascular dysfunction result in a more limited coronary vasodilatory response to increased oxygen demand and ensuing myocardial ischemia [2, 3] . In the clinical setting, coronary hyperemia can be achieved with exercise or pharmacologic interventions. Exercise, in the absence of endothelial-dysfunction or flow-limiting stenosis, is typically associated with a 2-to 3-fold increase in myocardial blood flow via an endothelium-dependent flow-mediated process to meet increasing myocardial oxygen demand [4] . Pharmacologic vasodilators (adenosine, dipyridamole, and regadenoson) are typically associated with a 3.5-to 4-fold increase in myocardial blood flow via arteriolar vasodilation through a direct and endothelium-mediated process [5] . Dobutamine, similar to exercise, is associated with a 2-to 3-fold increase in myocardial blood flow [5] .
PET Quantitative Perfusion Imaging
Experimental and clinical uses of PET have contributed significantly to the understanding of cardiac physiology and pathophysiology [6] . Although PET is considered the current gold standard for quantitative perfusion imaging, multiple factors have limited widespread clinical application including availability of scanners, increased cost, and reimbursement issues [7] .
PET Radiopharmaceuticals PET assessment of regional myocardial blood flow (MBF) entails dynamic acquisition of images during the intravenous injection of a positron-emitting perfusion tracer, such as 13 Nammonia, 15 O-water, 18 F-Flurpiridaz, or 82 Rubidium. 13 Nammonia and 82 Rubidium are the only FDA approved radiopharmaceuticals and thus, the most widely used perfusion tracers in clinical practice. 13 N-ammonia has a~10-minute physical half-life and requires an on-site cyclotron for production. 82 Rubidium has a~76-second half-life and is eluted from an on-site 82 Strontium generator. 13 N-ammonia has higher myocardial retention than 82 Rubidium and, therefore, is somewhat easier to quantify myocardial perfusion. Both radiopharmaceuticals are associated with a low radiation dose to the patient [8] . The newer PET imaging agent, 18 F-Flurpiridaz, which is currently in phase III clinical trials does not require an on-site cyclotron because of its long half-life (~110 min), has a high first-pass extraction with less roll-off compared with 13 N-ammonia and 82 Rubidium.
PET Imaging Protocol
The imaging protocol and duration of scan depends on the radiotracer that is used. For quantitative perfusion imaging, imaging begins with the injection of the radiotracer [9] [10] [11] . With 82 Rubidium or 15 O-water, the second study (stress or rest) can be performed without delay after the first study (stress or rest). However, with 13 N-ammonia the second study (stress or rest) is routinely delayed 30-50 min after the first study, to allow for radiotracer decay. Once postprocessed, images can be analyzed qualitatively and semiquantitatively as they are routinely clinically reported. Additionally, the dynamic acquisitions of the first pass of the tracer can be used for quantitative analysis deriving blood pool and tissue activity curves.
Quantitative Analysis
Tracer kinetic models for quantification of MBF by PET can yield regional MBF in absolute terms (ml/g/min) and have been shown to be highly correlated with MBF from microspheres in animal models over a wide range of flows [12] . These kinetic models compensate for underestimation of radiotracer concentration due to partial volume effect, spatial resolution, and cardiac motion [13] [14] [15] . In humans, 13 N-ammonia, 15 O-water, and 82 Rubidium provide a similar absolute MBF over a wide range of flows [16, 17] .
CMR Quantitative Perfusion Imaging
Improvements in magnetic resonance hardware and software development have enabled approaches with CMR to assess or measure myocardial blood flow. Compared with other methods in quantifying myocardial blood flow, CMR has the advantages of high spatial resolution (2-3 mm in-plane), high temporal resolution (110-130 ms), and lack of use of ionizing radiation (Table 1) . Current disadvantages of CMR quantification of myocardial blood flow include nonvolumetric ventricular coverage and relatively complex postprocessing steps involved. The most common form of CMR perfusion is based on acquisition of images of the myocardium during first-pass of an extravascular, extracellular contrast agent in combination with T 1 -weighted pulse sequences. Gadolinium, with 7 unpaired electrons, is one of the most effective paramagnetic agents, however, due to its toxicity, gadolinium is always chelated [18] . Gadolinium chelates are small sized agents that rapidly diffuse from the vascular space into the extravascular space and extra-cellular spaces, however, do not enter cells provided that the tissue cell membrane is intact [19] . The gadolinium chelates alter the local magnetic field, and in close proximity shorten both T 1 and T 2 relaxation times of protons. The shortening of T 1 relaxation time of a given tissue is proportional to the local gadolinium concentration in that tissue. Thus, after an intravenous bolus administration of contrast, myocardium that is well perfused will have a more substantial shortening of its T 1 relaxation time and appear brighter on T 1 weighted images, than myocardium that is not well perfused. Quantification of myocardial perfusion by CMR is possible by taking these factors into account.
CMR Imaging Protocol
The clinical CMR imaging protocol relies on qualitative assessment of ischemia and most commonly includes only myocardial perfusion during pharmacologic vasodilation and late gadolinium enhancement (infarct) imaging. Quantitative analysis of absolute myocardial blood flow (in ml/g/min) and blood flow reserve is currently only performed in research settings and requires both vasodilating and rest myocardial perfusion imaging datasets. The most common CMR perfusion imaging involves rapid acquisition of multiple short-axis slice locations every cardiac cycle for 40-80 cardiac cycles, immediately after injection of an intravenous bolus of gadolinium contrast, in order to capture the first-pass transit of the gadolinium bolus across cardiac structures. Fast imaging techniques such as fast gradient echo imaging, echo planar imaging, and steady-state-free precession imaging have been used in combination with accelerated image acquisition (known as parallel imaging) to reduce the acquisition time with some resultant reduction of signal-to-noise ratio [20, 21] . With the need to rapidly acquire images during the first-pass transit of the intravenous gadolinium bolus, typically only 4 slices (3-4 short axis slices and/or 1 long axis slice) are acquired every cardiac cycle. The current most common fast gradient echo or high heart rate method, fast low-angle single-shot (FLASH), imparts strong T1 contrast, which differentiates regions of hypoperfusion (ischemia or infarction) from normal perfusion, and provides ventricular coverage of relevant myocardial segments to include all American Heart Association / American College of Cardiology 17 segments [22] . Blood pool signal intensity during the first-pass transit of gadolinium is used as a reference in quantifying absolute myocardial blood flow, so special attention must be paid to the dosage of gadolinium. At low doses, the relationship between gadolinium concentration (which reflects blood flow) and the measured signal intensity is approximately linear [23] , however, at higher doses (>0.12 mmol/kg) the relationship is no longer linear and there can be signal saturation that prohibits quantitation of absolute myocardial blood flow [21] . Visual or semiquantitative analysis is easier at higher doses (0.1-0.15 mmol/kg) because of greater contrast-to-noise, however, quantitative analysis would be less reliable because of signal saturation. Clinical studies have been traditionally performed at higher doses, and qualitative visual interpretation yields consistent high diagnostic accuracies [24, 25, 26 ••]. However, clinical scans performed with higher doses of gadolinium cannot retrospectively extract information about absolute myocardial blood flow or blood flow reserve. New CMR perfusion methods at specialized centers employ imaging during administration of gadolinium chelate contrast agents as a dual-bolus. The first low dose bolus enables quantitative analysis of the myocardial blood flow and the second high dose bolus provides the ability to visualize perfusion defects [27, 28•] .
Quantitative Analysis CMR techniques for quantification of MBF can also yield regional MBF in absolute terms (ml/g/min). As with PET, most techniques involve regional analysis of the timeintensity curves. The myocardium is segmented during sequential phases, tracking a consistent portion of the left ventricle while avoiding blood pool contamination and errors from respiratory motion. For semiquantitative analysis, signal intensity (SI) within the regions of interest are depicted as a function of time, which provides the rate of increase in SI or upslope after the bolus of contrast, the maximum SI increase, the time to maximum SI increase, the time from contrast appearance in the left ventricular cavity to the contrast appearance into the myocardium, the rate of decrease in SI after peak, and the mean transit time of contrast [21] . Using the upslope of the curve at peak hyperemia and at rest, the myocardial perfusion reserve or CFR can be calculated (CFR = upslope of SI during hyperemia / upslope of SI at rest) ( Fig. 1) [29] .
Absolute quantification of MBF can be made when there is a quantifiable relationship between the SI in the image and underlying blood flow. The measured arterial input function, usually derived from the signal time curves from a region of interest in the left ventricular cavity or ascending aorta, and tissue function enhancement are then applied with [108] mathematical deconvolution to compute myocardial perfusion. Mathematical deconvolution can be performed using the time-intensity curve and one of several models, including a compartmental kinetic model, the Fermi [30] , or modified Kety [31] model. Quantitative CMR perfusion has been shown to be highly correlated with MBF from microspheres in animal models [32] , and compared with other established imaging modalities, including PET [33-35, 36•, 37] and invasive fractional flow reserve [38, 39] .
CT Quantitative Perfusion Imaging
A routine coronary computed tomography angiography (CTA) scan can detect a wide range of disease from mild nonobstructive coronary artery disease with calcified or noncalcified plaque to occluded vessels; however, the functional significance of some anatomic lesions is often unknown [40] [41] [42] . Among patients who require both myocardial perfusion imaging (MPI) and an evaluation for coronary anatomy, using a single modality, which can simultaneously image both coronary anatomy and evaluate for myocardial perfusion may be advantageous. Multiple single-center studies and 2 multicenter studies have evaluated the capability of combining coronary CTA and CTP to detect both the presence of coronary artery disease and myocardial perfusion abnormalities [43] [44] [45] [46] [47] [48] [49] [50] .
Myocardial perfusion imaging with CTP requires the acquisition of an electrocardiogram (ECG) gated intravenous iodinated contrast enhanced CT during vasodilator stress. The intravenous iodinated contrast attenuates x-rays proportional to its concentration and scan acquisition is timed during the early first pass of contrast into the myocardium to observe differences in the inflow of contrast and therefore differences in attenuation of normal and ischemic or infarcted myocardium [51] .
CTP Imaging Protocol
Myocardial CTP protocols include a stress and rest acquisition, similar to PET. A time interval between the 2 scans is important to avoid the possibility of contrast in the myocardium at the time of the second acquisition, which may reduce the sensitivity to detect ischemia if the stress scan is the second acquisition. Regardless if it is performed first or second, the rest CTP scan is also used for interpretation of CTA and, thus, requires administration of nitrates and beta-blockers in order to optimize the visualization of the coronary arteries. An advantage of obtaining the rest scan first, is that if no or mild CAD is present, no stress perfusion scan would be needed.
Several CTP acquisition protocols have been used, some of which are specific to particular scanners. Stress CTP can be acquired using single-phase acquisitions or dynamic acquisitions. The single-phase stress and rest acquisitions are acquired using axial acquisition with prospective ECG triggering during diastole and are associated with a relatively low dose of radiation [52] . Alternatively, helical acquisition with retrospective ECG gating and tube current modulation can also be used, and offer the ability to evaluate the ejection fraction, abnormal wall motion during peak stress as well as to assess myocardial perfusion during multiple phases of the cardiac cycle. Scanners with a larger coverage along the z-axis may minimize misregistration artifacts while dual source CT scanners provide improved temporal resolution, and therefore may reduce motion artifacts. Multiple vendors offer the capability to use dual-energy scanning to provide an iodine distribution map based on the CT image sets obtained by the 2 different energy levels. However, there is no evidence to suggest that this technique improves the diagnostic accuracy of CTP to identify ischemia or scar. Assessment of myocardial perfusion by the aforementioned techniques are performed using qualitative or semiquantitative methods since only 1 data set is acquired with images, which correspond to only a portion of the first pass of contrast into the myocardium.
Dynamic myocardial perfusion uses serial CT imaging over time to obtain multiple data sets and, thus, allow for calculation of the kinetics of iodinated contrast in the arterial blood pool and myocardium over time [44, 51, [53] [54] [55] . Dynamic imaging can be performed while the scanner's table is stationary if there is enough coverage in the z-axis, or in a shuttle-mode where the scanner rapidly alternates between table positions to allow for increased coverage. The advantage of dynamic imaging is that it allows for absolute quantification of MBF, while the main disadvantage is that it is associated with a 3-4 fold higher radiation exposure. In animal models, both dynamic and single-phase acquisitions, are able to detect hypoperfusion in poststenotic myocardial segments for higher degrees of coronary stenosis (75 %) [56] . Additionally, the density measurements on single-phase acquisitions correlate well with microsphere-derived estimates of MBF [43] . However, dynamic acquisition techniques may allow for the identification of more subtle perfusion changes at moderate stenosis (50 %) [56] .
Quantitative Analysis
The first studies to measure and quantify MBF using CT were performed with electron beam computed tomography (EBCT). Investigators demonstrated a strong correlation of EBCT-derived myocardial perfusion metrics with microsphere-derived MBF [57] [58] [59] . Dynamic EBCT was further validated in an animal study and in healthy volunteers with maximal vasodilatation and at rest [60] . EBCTs had limited spatial resolution, and with multidetector scanning, EBCTs are now no longer used. Multidetector CT (MDCT) technology has evolved from 4, 16, and 64 detector systems to scanners with 128, 256, and 320 detectors. At the same time, dual source CT scanners as well as faster gantry rotation has allowed for improved temporal resolution [59] .
In in vivo animal experiments, dynamic acquisition allows for the detection and quantification of ischemic myocardium [53] . CT derived MBF from dynamic acquisitions can also differentiate various degrees of coronary artery stenosis, which correlate well with fractional flow reserve measurements [61, 62] . The multiple data sets obtained from the dynamic images can be used to construct time activity curves (TAC) of the aorta and left ventricle. CT derived MBF can be quantified based on several techniques ranging from modelbased deconvolution techniques, upslope analysis or Patlak plot analysis [44, 59] . In deconvolution techniques, which require imaging throughout the contrast bolus as contrast transits through blood pool and myocardium, CT measured attenuation is converted to iodine concentration and TAC become time-iodine concentration curves. Spatially distributed two-compartment models are made representing the vascular and interstitial spaces for arterial input and myocardial time iodine concentration curves, which have a strong correlation with microsphere derived MBF [59] . Upslope analysis, which was adapted from MRI studies and requires just a portion of the contrast bolus, provides a semiquantitative measure of myocardial perfusion using TAC from a linear fit line to the time when contrast is first detected in the LV blood pool to the data point when peak contrast enhancement is detected in the respective myocardium (Fig. 1) [44, 59, 63] . Patlak plot analysis uses fewer sampling points in the TAC and requires only data from the upslope of the contrast bolus. The Patlak plot method is based on a 2-compartment pharmacokinetic model, which allows for the calculation of the firstorder transfer constant from LV blood to myocardium by changes in attenuation [59] .
Studies of CTP using MDCT in humans have mostly been static imaging of contrast distribution at single time points during stress and rest [45, 46] , or rest only [64, 65] . The CORE320 study, a multicenter international study, evaluated the combination of CT angiography and CTP in comparison to invasive coronary angiography and SPECT. In this study, dynamic bolus tracking at the level of the descending aorta was used to acquire a single-phase volumetric acquisition of the myocardium before peak contrast enhancement in the myocardium [66] . The area under the receiver operating characteristic curve for the combination of CTA and single-phase perfusion was 0.87 (with 95 % confidence intervals [CI] of 0.84-0.91) for correctly identifying patients with flow limiting CAD as defined as ≥50 % stenosis [67] . The findings of the CORE320 study are promising, and further advances in CT technology should enhance the ability to obtain diagnostic CTP images at lower radiation doses. There is early evidence that future optimization and the adoption of reconstruction techniques such as iterative reconstruction may further reduce the radiation exposure associated with CTP while providing similar image quality [68] . Taking advantage of these advances, further studies are needed to compare the diagnostic accuracy and radiation dose of static single-phase CTP compared with dynamic CTP with quantitative assessment in humans.
Clinical Applications of Quantitative Myocardial Perfusion

CAD Detection
Preliminary reports of clinical feasibility for quantitative PET and CMR have been preceded by multiple clinical studies employing qualitative or semiquantitative interpretations confirming their feasibility and their diagnostic performance in evaluating anatomically and functionally defined coronary artery disease [2] . PET for detecting obstructive CAD has been extensively documented, and the mean sensitivity for detecting greater than 50 % angiographic stenosis was 89 % and the mean specificity was 87 % [69-75, 76•] . CMR has compared favorably with the values obtained with PET [76•], with sensitivity and specificity reports of 87 and 85 %, respectively [33] . In the single-center CE-MARC study that directly compared Stress CMR with SPECT, CMR was found to have a higher sensitivity but similar specificity as SPECT [26••] . To date, 2 studies have examined the diagnostic accuracy of CTP with CMR, both with similar accuracy [52, 77] . Comparisons with invasive physiological measurements such as fractional flow reserve have also yielded similar results [38, 39, 62, [78] [79] [80] .
As discussed above, a recognized limitation of radionuclide MPI with both PET and SPECT is that it often uncovers only coronary territories supplied by coronary arteries with the most severe stenosis, and consequently, it is relatively insensitive to accurately delineate the extent of obstructive angiographic CAD especially in the setting of multivessel CAD [1, 81] . A number of studies have demonstrated that among relatively young patients with modest coronary risk factor burden and predominantly single-vessel CAD, a relationship exists between myocardial blood flow or CFR and percent diameter stenosis on angiography [2, 3, 82] These studies demonstrate that CFR is relatively preserved for lesions with less than 50 % stenosis. With increasing severity of stenosis beyond this level, however, there is progressive worsening of coronary flow reserve. These observations have served as the basis for the clinical use of quantitative myocardial blood flow to improve identifications of obstructive CAD, and especially to exclude the presence of angiographic multivessel CAD (Fig. 2) [83, 84, 85•] . In the largest study to date [85•] , the presence of a relatively normal global CFR (>2.0) in patients with normal or abnormal myocardial perfusion scans was associated with a very low likelihood of high-risk angiographic CAD (NPV: 97 %).
Incremental Risk Stratification
Quantitative myocardial perfusion is also emerging as a powerful tool for risk stratification in CAD, as well as other clinical conditions (eg, hypertrophic cardiomyopathy) [86] . Indeed, coronary flow reserve provides a robust and reproducible clinical measure of the integrated hemodynamic effects of epicardial CAD, diffuse atherosclerosis, vessel remodeling, and microvascular dysfunction on myocardial tissue perfusion. Consequently, it is a more sensitive measure of myocardial ischemia and overall vascular health that provides unique information about clinical risk. The available data suggest that CFR measurements by PET can distinguish patients at high risk for serious adverse events, including cardiac death [87••, 88-90] . Indeed, a severely reduced CFR (<1.5) was associated with a 6-fold increased risk of cardiac death, even after adjusting for differences in clinical risk, the extent and severity of ischemia and scar, and LVEF, and led to clinically meaningful riskreclassification of~50 % of intermediate risk patients [87••] . Importantly, an abnormal CFR identified patients at increased risk of cardiac death even among those normal scans by semiquantitative visual analysis (Fig. 3) . These findings are also applicable to high-risk cohorts, including patients with diabetes and chronic renal impairment [91, 92•] . For example, a reduced global CFR is independently associated with higher rates of cardiac and all-cause mortality in a large cohort of patients with and without diabetes mellitus. Compared with diabetics with preserved CFR, those with reduced CFR experienced substantially higher cardiac mortality (Fig. 4) [92•] . Importantly, diabetic patients without known CAD and with impaired CFR experienced a rate of cardiac death comparable to, and possibly higher than, that for nondiabetic patients with known CAD. These observations have implications for the classification of diabetes mellitus as a coronary disease risk equivalent [93] . Specifically, only among diabetics with impaired vascular function is prognosis comparable with nondiabetic patients with known CAD. Thus, differing levels of vascular health among previously studied cohorts may account for inconsistencies in relative mortality rates of diabetics without CAD and nondiabetics with CAD [94] [95] [96] . An abnormal myocardial perfusion CMR is also associated with an increased risk of death or nonfatal infarction beyond traditional risk factors [97, 98•] . A normal perfusion study is associated with a very low event rate [87••, 97, 99] .
Nonetheless, in the absence of randomized controlled studies that evaluate treatment effect it remains unclear if obtaining an abnormal CFR by any modality will impact on the final outcome [100•] . Quantitative assessment of MBF by PET, CMR, or CTP may be a useful surrogate marker for disease activity and may be determined to have prognostic implications [101] [102] [103] [104] . Further studies are needed to see if quantitative assessment of MBF would be useful to monitor therapeutic response to interventions.
Selecting Patients for Revascularization
The severity of angiographic coronary artery stenosis had previously been the guide to select lesions for revascularization. However, in patients with nonacute 
Conclusions and Future Directions
PET, CMR, and CTP are rapidly evolving, and quantitative assessment of myocardial blood flow has the potential to improve the accuracy of detecting the presence of CAD, diagnosing multivessel and the functional importance of hemodynamically significant epicardial disease, and improve risk assessments for individual patients in an observer-independent and reproducible method. Although PET has been the most extensively studied, there is good correlation between PET and CMR determined CFR [36•] and the basic concepts of being able to quantitate coronary physiology directly and reliably by any technology may have a unique role in coronary artery disease detection, risk stratification, and selecting patients for revascularization. Even though current studies demonstrate that flow quantification can be applied to clinical PET and clinical CMR perfusion, further studies are needed to further reduce radiation exposure and determine the feasibility, and incremental value, of quantitative CTP in humans.
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